Intas and Axantia sign an exclusive agreement for Ranibizumab biosimilar
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
Arzeda harnesses the power of computer-designed enzymes and applies the latest advances in digital biology
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
BVX-0922 to target colorectal cancer under investigator-sponsored IND
A major unresolved question in the field, however, is how do this machinery rapidly searches for and finds rare stretches of damage amid the "vast fields" of undamaged DNA
The event will have a mix of policymakers, national and international leaders from the pharma industry, MSME, innovators, academic and research fraternity
The selected 49 applications are from 33 companies. Out of these 33 companies, 13 are Micro, Small and Medium Enterprises (MSMEs) besides some newly incorporated entities
The summit also saw the launch of two important reports- Multi-Regional Clinical Trials (MRCT) and Value of OTC in India
The collaboration will utilize Avatar-Rx, LifeMine’s proprietary genomically-enabled drug discovery platform to access evolutionarily derived lead small molecules
Subscribe To Our Newsletter & Stay Updated